Regulation of c-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells

S. D. Gowda, R. D. Koler, G. C. Bagby

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    C-myc proto-oncogene transcripts from serially harvested, colony-stimulating activity (CSA)-stimulated, normal progenitor-enriched human bone marrow cells were compared to those of the promyelocytic leukemia cell line HL-60 and to those of freshly obtained human myeloid leukemic cells. During the early culture period both normal and leukemic cells expressed the c-myc oncogene. In normal cells maximal expression occurred after 24 h of culture and did not occur in the absence of CSA. At this time, progranulocytes predominated in the cultured cells. Although cellular proliferation occurred for 96 h in vitro, c-myc expression ceased after 24-36 h. Terminally differentiated cells predominated in these cultures by 120 h. In contrast, although leukemic cells also expressed c-myc in vitro, transcription persisted throughout the culture period and, in the case of HL-60 cells, occurred in the absence of exogenous CSA. We also noted that normal cells with only one diploid gene copy exhibited, after 24 h of culture, only twofold fewer transcripts than did HL-60 cells in which there were 16 myc copies. Furthermore, c-myc mRNA degradation rates were similar in normal cells and in HL-60 cells. We conclude that c-myc transcription is a normal event in granulopoiesis linked to proliferative activity as well as to primitive development stage. Furthermore, the most consistent abnormality in leukemic cells in vitro is their failure to suppress transcriptional activity of this gene. We suggest that c-myc transcription in HL-60 cells may be appropriate for cells arrested at the developmental stage and that the amplified genes in HL-60 cells are quiscent relative to c-myc in normal cells at the same differentiation stage. The techniques described herein may be of value in identifying mechanisms by which normal hematopoietic cells suppress c-myc expression and aberrancies of these mechanisms in leukemic cells.

    Original languageEnglish (US)
    Pages (from-to)271-278
    Number of pages8
    JournalJournal of Clinical Investigation
    Volume77
    Issue number1
    StatePublished - 1986

    Fingerprint

    Myeloid Progenitor Cells
    Growth
    HL-60 Cells
    myc Genes
    Genes
    Granulocyte Precursor Cells
    Proto-Oncogenes
    RNA Stability
    Myeloid Cells
    Diploidy
    Bone Marrow Cells
    Cultured Cells
    Leukemia

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Regulation of c-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells. / Gowda, S. D.; Koler, R. D.; Bagby, G. C.

    In: Journal of Clinical Investigation, Vol. 77, No. 1, 1986, p. 271-278.

    Research output: Contribution to journalArticle

    @article{8a063397debc437f8184f20d5c3ee554,
    title = "Regulation of c-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells",
    abstract = "C-myc proto-oncogene transcripts from serially harvested, colony-stimulating activity (CSA)-stimulated, normal progenitor-enriched human bone marrow cells were compared to those of the promyelocytic leukemia cell line HL-60 and to those of freshly obtained human myeloid leukemic cells. During the early culture period both normal and leukemic cells expressed the c-myc oncogene. In normal cells maximal expression occurred after 24 h of culture and did not occur in the absence of CSA. At this time, progranulocytes predominated in the cultured cells. Although cellular proliferation occurred for 96 h in vitro, c-myc expression ceased after 24-36 h. Terminally differentiated cells predominated in these cultures by 120 h. In contrast, although leukemic cells also expressed c-myc in vitro, transcription persisted throughout the culture period and, in the case of HL-60 cells, occurred in the absence of exogenous CSA. We also noted that normal cells with only one diploid gene copy exhibited, after 24 h of culture, only twofold fewer transcripts than did HL-60 cells in which there were 16 myc copies. Furthermore, c-myc mRNA degradation rates were similar in normal cells and in HL-60 cells. We conclude that c-myc transcription is a normal event in granulopoiesis linked to proliferative activity as well as to primitive development stage. Furthermore, the most consistent abnormality in leukemic cells in vitro is their failure to suppress transcriptional activity of this gene. We suggest that c-myc transcription in HL-60 cells may be appropriate for cells arrested at the developmental stage and that the amplified genes in HL-60 cells are quiscent relative to c-myc in normal cells at the same differentiation stage. The techniques described herein may be of value in identifying mechanisms by which normal hematopoietic cells suppress c-myc expression and aberrancies of these mechanisms in leukemic cells.",
    author = "Gowda, {S. D.} and Koler, {R. D.} and Bagby, {G. C.}",
    year = "1986",
    language = "English (US)",
    volume = "77",
    pages = "271--278",
    journal = "Journal of Clinical Investigation",
    issn = "0021-9738",
    publisher = "The American Society for Clinical Investigation",
    number = "1",

    }

    TY - JOUR

    T1 - Regulation of c-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells

    AU - Gowda, S. D.

    AU - Koler, R. D.

    AU - Bagby, G. C.

    PY - 1986

    Y1 - 1986

    N2 - C-myc proto-oncogene transcripts from serially harvested, colony-stimulating activity (CSA)-stimulated, normal progenitor-enriched human bone marrow cells were compared to those of the promyelocytic leukemia cell line HL-60 and to those of freshly obtained human myeloid leukemic cells. During the early culture period both normal and leukemic cells expressed the c-myc oncogene. In normal cells maximal expression occurred after 24 h of culture and did not occur in the absence of CSA. At this time, progranulocytes predominated in the cultured cells. Although cellular proliferation occurred for 96 h in vitro, c-myc expression ceased after 24-36 h. Terminally differentiated cells predominated in these cultures by 120 h. In contrast, although leukemic cells also expressed c-myc in vitro, transcription persisted throughout the culture period and, in the case of HL-60 cells, occurred in the absence of exogenous CSA. We also noted that normal cells with only one diploid gene copy exhibited, after 24 h of culture, only twofold fewer transcripts than did HL-60 cells in which there were 16 myc copies. Furthermore, c-myc mRNA degradation rates were similar in normal cells and in HL-60 cells. We conclude that c-myc transcription is a normal event in granulopoiesis linked to proliferative activity as well as to primitive development stage. Furthermore, the most consistent abnormality in leukemic cells in vitro is their failure to suppress transcriptional activity of this gene. We suggest that c-myc transcription in HL-60 cells may be appropriate for cells arrested at the developmental stage and that the amplified genes in HL-60 cells are quiscent relative to c-myc in normal cells at the same differentiation stage. The techniques described herein may be of value in identifying mechanisms by which normal hematopoietic cells suppress c-myc expression and aberrancies of these mechanisms in leukemic cells.

    AB - C-myc proto-oncogene transcripts from serially harvested, colony-stimulating activity (CSA)-stimulated, normal progenitor-enriched human bone marrow cells were compared to those of the promyelocytic leukemia cell line HL-60 and to those of freshly obtained human myeloid leukemic cells. During the early culture period both normal and leukemic cells expressed the c-myc oncogene. In normal cells maximal expression occurred after 24 h of culture and did not occur in the absence of CSA. At this time, progranulocytes predominated in the cultured cells. Although cellular proliferation occurred for 96 h in vitro, c-myc expression ceased after 24-36 h. Terminally differentiated cells predominated in these cultures by 120 h. In contrast, although leukemic cells also expressed c-myc in vitro, transcription persisted throughout the culture period and, in the case of HL-60 cells, occurred in the absence of exogenous CSA. We also noted that normal cells with only one diploid gene copy exhibited, after 24 h of culture, only twofold fewer transcripts than did HL-60 cells in which there were 16 myc copies. Furthermore, c-myc mRNA degradation rates were similar in normal cells and in HL-60 cells. We conclude that c-myc transcription is a normal event in granulopoiesis linked to proliferative activity as well as to primitive development stage. Furthermore, the most consistent abnormality in leukemic cells in vitro is their failure to suppress transcriptional activity of this gene. We suggest that c-myc transcription in HL-60 cells may be appropriate for cells arrested at the developmental stage and that the amplified genes in HL-60 cells are quiscent relative to c-myc in normal cells at the same differentiation stage. The techniques described herein may be of value in identifying mechanisms by which normal hematopoietic cells suppress c-myc expression and aberrancies of these mechanisms in leukemic cells.

    UR - http://www.scopus.com/inward/record.url?scp=0022575722&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0022575722&partnerID=8YFLogxK

    M3 - Article

    C2 - 3511091

    AN - SCOPUS:0022575722

    VL - 77

    SP - 271

    EP - 278

    JO - Journal of Clinical Investigation

    JF - Journal of Clinical Investigation

    SN - 0021-9738

    IS - 1

    ER -